Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Strange that it went down more on the last couple of days on much lower vol? Vols not as low since June.
tomorrow will be interesting to see how the MMs behave

Jumpin - indeed.

Up a couple of p just now.

Uptrend seems to have held. Nice looking hammer now.

Now up 7.58%

MMs behaved exactly as I thought they would!

Nice one Jumpin

Big Al-Hammer? Where did the carpenter come from?very strange this BPRG;-)

thanks for equis link,very good

JC, m8. Looking after all the "average-downers".

LOL!

Don't need a book in charting, just watch for the "bend at the end of the trend". See one?

If we have to get technical, there is always the uptrend in RSI in chart above not to mention higher low (or 1-2-3) at 60p. Not entirely surprising as 60p was a pig to breakthrough going north.

Off to kiss the Blarney Stone now. Hope I don't fall off.

Saw it the other week Bones. ;-))

Still not an uptrend, but stands a decent chance of getting one underway. Still think 75/80p gonna be tricky, though. She'll be on a flyer when/if it happens.

Bones-we've got shooting stars,hammers,black holes,do we really need the Blarney Stone as well?LOL

emailpat - LOL!

Rather disappointed to see a lack of anything today. Price dropped, no volume, etc. In fact lowest volume in 3 months!!

PRM might have made people realise what can happen if news does go against you.

Ne'er mind - next week's another week (funnily enough), so we'll see what happens, but definitely getting the impression the fizz is going, be it "up-fizz" or "down-fizz". Typical closed period?

BioProgress appoints JPMorgan for US Nasdaq listing
http://www.uk-wire.com/cgi-bin/articles/200408040700155964b.html

Brokers note finally out. Interesting that they say "as broker to the company we make no recomendation and leave investors to draw their own conclusions as to the value of the company. Thought they might have said stonking buy !

Janus, sounds like CS do not know how to value the company then!!

Janus, thats probably they are going to be replaced with alarger and more commited broker, who will put the interests of BPRG and its shareholders first.

CS are a bunch of crooks

Year to December 2003A 2004E 2005E 2006E
Turnover (m) 0.9 5.4 14.4 32.8
Pre-tax profit (m) (1.7) 1.5 5.9 13.1
EPS (p) (3.4) 1.3 4.1 8.0
P/E (x) n/a 46.1 14.6 7.5
Cash (m) 1.8 12.0 14.1

I especially like this bit:

In summary this is a disruptive technology in one of the worlds largest
industries. Given the strong Intellectual Property that exists on the
technology, operating margins should be very strong and profitability in
2006/07 enough to drive forward the valuation. Our estimates for 2006
should be viewed as conservative, with the companys own internal targets
being 3x our estimated level of profitability.

BioProgress investors have had a real roller coaster of a ride since our feature back in October 2003 at 55p; the shares progressed to an all time high of 158p in February, since then the shares have steadily re-traced back to a low point of 60p on July 7.

Todays 14% thrust north to 71p can be attributed JPMorgan appointment, and of course, the long awaited Collins Stewart broker note; the first of its kind since the company floated on the AIM market just over a year ago. BioProgress announced that JPMorgan Chase Bank has been appointed as the US depositary for BioProgress listing of its Ordinary Shares in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market in the USA, JPMorgan should help drum up US support for BPRG.

BioProgress looks have a three pronged turbine thrust developing behind it; There can be little doubt that such a high profile blue chip appointment in JPMorgan should increased buy pressure once London listed shares are transferred to the US as ADRs. Observers have suggested to me that 20p up side can be expected per million shares transferred as ADRs. I must confess to a head ache once I digested the complexity of the example when explained to me.no I am not going to try! Moving swiftly on.


BioProgress investors have had a real roller coaster of a ride since our feature back in October 2003 at 55p; the shares progressed to an all time high of 158p in February, since then the shares have steadily re-traced back to a low point of 60p on July 7.

Todays 14% thrust north to 71p can be attributed JPMorgan appointment, and of course, the long awaited Collins Stewart broker note; the first of its kind since the company floated on the AIM market just over a year ago. BioProgress announced that JPMorgan Chase Bank has been appointed as the US depositary for BioProgress listing of its Ordinary Shares in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market in the USA, JPMorgan should help drum up US support for BPRG.

BioProgress looks have a three pronged turbine thrust developing behind it; There can be little doubt that such a high profile blue chip appointment in JPMorgan should increased buy pressure once London listed shares are transferred to the US as ADRs. Observers have suggested to me that 20p up side can be expected per million shares transferred as ADRs. I must confess to a head ache once I digested the complexity of the example when explained to me.no I am not going to try! Moving swiftly on.


BioProgress investors have had a real roller coaster of a ride since our feature back in October 2003 at 55p; the shares progressed to an all time high of 158p in February, since then the shares have steadily re-traced back to a low point of 60p on July 7.

Todays 14% thrust north to 71p can be attributed JPMorgan appointment, and of course, the long awaited Collins Stewart broker note; the first of its kind since the company floated on the AIM market just over a year ago. BioProgress announced that JPMorgan Chase Bank has been appointed as the US depositary for BioProgress listing of its Ordinary Shares in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market in the USA, JPMorgan should help drum up US support for BPRG.

BioProgress looks have a three pronged turbine thrust developing behind it; There can be little doubt that such a high profile blue chip appointment in JPMorgan should increased buy pressure once London listed shares are transferred to the US as ADRs. Observers have suggested to me that 20p up side can be expected per million shares transferred as ADRs. I must confess to a head ache once I digested the complexity of the example when explained to me.no I am not going to try! Moving swiftly on.